Novel microneedle method shows efficacy for keloid treatment

  • Tan CWX & al.
  • Dermatol Ther (Heidelb)
  • 2 Aug 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dissolving triamcinolone-embedded microneedles are associated with significant keloid volume reductions, according to results from a small clinical trial.

Why this matters

  • Corticosteroid injections, the standard first-line treatment, are associated with significant pain.

Key results

  • Microneedle treatment was associated with reduced keloid volume after 4 weeks (mean change, −9.1 mm3; P=.001); control keloids increased in size during this period (mean change, +7.2 mm3; P=.104; P=.019 for treated vs control keloids; phase 1).
  • In a second treatment and analysis conducted 6 months later with a 4 times higher dose of triamcinolone (phase 2), microneedle treatment was again associated with reduced keloid volume after 4 weeks (mean change, −22.1 mm3; P=.001); control keloids increased in size during this time (mean change, +6.7 mm3; P=.545; P=.035 for treated vs control keloids).
    • The treatment-associated reduction in keloid volume in phase 2 was significantly higher than in phase 1 (P=.029).

Study design

  • 27 patients with keloids were included; 2 similar keloids on each patient either received microneedle treatment or served as a control.
  • Funding: National Medical Research Council, Singapore.

Limitations

  • Small patient sample size.
  • Treatment was based on easy-to-reach keloid location and not randomized.
  • Significant differences in baseline volumes of control vs treated keloids.